Preclinical studies have reported that increased levels of cyclin D1 and CDK4 confer resistance to HER2-inhibitors in tumor cells, and CDK4/6 inhibitor can regain the sensitivity to HER2-directed agents (13). This evidence concerns the gene ERBB2 and neoplasm.